LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)

Emphysema Clinical Trial

— CROSSOVER  

Official title:

Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02059057
• Other study ID #: CLN0016
• Status: Terminated
• Phase: N/A
• Start date: December 2013
• Est. completion date: July 26, 2019

Study information

• Verified date: July 2021
• Source: Boston Scientific Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Crossover study for patients who were randomized to the Control Group in CLN0009 (NCT01608490).

Description:

Provide LVRC procedure to qualifying subjects who were enrolled as Control Subjects in and completed the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009, and obtain safety and effectiveness data on these patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 102
• Est. completion date: July 26, 2019
• Est. primary completion date: June 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 36 Years and older

Eligibility

Inclusion Criteria:

1. Subject was enrolled as a Control Subject in and completed all required study assessments through the 12 month visit for the Lung Volume Reduction Coil Treatment in Patients with Emphysema (RENEW) Study, CLN0009.

2. Subject has post-bronchodilator FEV1 =45% predicted.

3. Subject has residual volume (RV) =175% predicted.

4. Subject has stopped smoking for at least 8 weeks prior to entering the study, as confirmed by a Cotinine test or other appropriate diagnostic test.

5. Subject has read, understood and signed the Informed Consent form.

6. Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.

Exclusion Criteria:

1. Subject has severe homogeneous emphysema as determined by the Core Radiology Lab

2. Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g. severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.

3. Subject has a change in FEV1 >20% (or, for subjects with pre-bronchodilator FEV1 below 1 L, a change of > 200 mL) post-bronchodilator, unless investigator can confirm by other means that subject does not have asthma.

4. Subject has DLCO <20% of predicted.

5. Subject has severe gas exchange abnormalities as defined by:

PaCO2 >55 mm Hg PaO2 <45 mm Hg on room air (High altitude criterion: PaO2 <30 mm Hg)

6. Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.

7. Subject has severe pulmonary hypertension. If pulmonary hypertension is present, "severe" is defined by right ventricular systolic pressure >50 mm Hg via right heart catheterization and/or echocardiogram.

8. Subject has an inability to walk >140 meters (150 yards) in 6 minutes.

9. Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.

10. Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.

11. Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.

12. Subject has clinically significant bronchiectasis.

13. Subject has giant bullae >1/3 lung volume.

14. Subject has had previous LVR surgery, lung transplantation, lobectomy, LVR devices or other devices to treat COPD in either lung.

15. Subject has been involved in pulmonary drug or device studies within 30 days prior to this study, with the exception of the RENEW Study.

16. Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily.

17. Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.

18. Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for seven (7) days prior to procedure.

19. Subject has a sensitivity or allergy to nitinol (nickel-titanium) or its constituent metals.

20. Subject has a known sensitivity to drugs required to perform bronchoscopy.

21. Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).

22. Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes. -

Related Conditions & MeSH terms

• Emphysema
• Pulmonary Emphysema

Intervention

Device:
• LVRC System

Locations

Country	Name	City	State
Canada	Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)	Quebec
France	Centre Hospitalier Universitaire de Nice	Nice
France	CHU de Reims - Hopital Maison Blanche	Reims
Netherlands	University Medical Center Groningen	Groningen
United Kingdom	Royal Brompton Hospital & Chelsea Westminster	London
United States	University of Michigan Health System	Ann Arbor	Michigan
United States	University of Alabama Lung Health Center	Birmingham	Alabama
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Medical University of South Carolina	Charleston	South Carolina
United States	Northwestern University	Chicago	Illinois
United States	The Cleveland Clinic	Cleveland	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Florida	Gainesville	Florida
United States	Pulmonary, Critical Care & Sleep Medicine Consultants,PCCS/St. Luke's Episcopal Hospital	Houston	Texas
United States	Cedars Sinai Medical Center	Los Angeles	California
United States	University of Wisconsin School of Medicine & Public Health	Madison	Wisconsin
United States	El Camino Hospital/Palo Alto Medical Foundation	Mountain View	California
United States	Yale University School of Medicine - Yale New Haven Hospital	New Haven	Connecticut
United States	New York Presbyterian Columbia University Medical Center	New York	New York
United States	Illinois Lung and Critical Care Institute	Peoria	Illinois
United States	Temple	Philadelphia	Pennsylvania
United States	Emphysema COPD Research Center, University of Pittsburgh	Pittsburgh	Pennsylvania
United States	Mayo Clinic	Rochester	Minnesota
United States	University of Texas Health Sciences Center at San Antonio	San Antonio	Texas
United States	Franciscan Research Center	Tacoma	Washington

Sponsors (2)

Lead Sponsor	Collaborator
Boston Scientific Corporation	PneumRx, Inc.

Countries where clinical trial is conducted

United States,  Canada,  France,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean Change in Six Minute Walk Test (6MWT)	Mean absolute change from baseline to12 months. The six-minute walk test (6MWT) measures the distance an individual is able to walk over a total of six minutes on a hard, flat surface. The goal is for the individual to walk as far as possible in six minutes. The individual is allowed to self-pace and rest as needed as they traverse back and forth along a marked walkway.	Change in Baseline to 12 months
Secondary	Mean Percent Change in Forced Expiratory Volume in One Second (FEV1)	The forced expiratory volume in one second (FEV1) measurement shows the amount of air a person can forcefully exhale in one second. Typically, lower FEV1 scores show more severe stages of lung disease. A positive change in FEV1 indicates improvement in lung function.	Change in Baseline to 12 months
Secondary	Mean Change in Residual Volume (RV)	Residual volume is the amount of air that remains in a person's lungs after fully exhaling. A decrease in residual volume indicates improvement in patients with higher residual volume measures.	Change in Baseline to 12 months
Secondary	Mean Change in St. Georges Respiratory Questionnaire (SGRQ)	Measure Description: The SGRQ is designed to measure health impairment in patients with asthma and COPD.; It consists of 50 items and has two parts: Part I (Symptoms): several scales; Part II (Activity and Impacts): dichotomous (true/false) except last question (4-point Likert scale); Scores range from 0 to 100, with higher scores indicating more limitations.; A negative change in score indicates improvement, with a mean change of 4 points being the minimal important difference.	Change in Baseline to 12 months